Literature DB >> 8275781

The third epidemic--multidrug-resistant tuberculosis.

K Neville1, A Bromberg, R Bromberg, S Bonk, B A Hanna, W N Rom.   

Abstract

We recently observed a striking increase in multidrug-resistant tuberculosis (MDR-TB) among patients admitted to the Chest Service at Bellevue Hospital Center in New York. We reviewed the laboratory susceptibility test results of 4,681 tuberculosis (TB) cases over the past 20 years, Combined resistance to isoniazid and rifampin increased from 2.5 percent in 1971 to 16 percent in 1991 with higher rates noted for individual drugs. We reviewed the medical records of 100 patients with drug-resistant TB, finding that these individuals were predominantly less than 40 years of age, minority, male, jobless, undomiciled, with a high percentage of drug abuse and human immunodeficiency virus infection. We conclude that the epidemics of AIDS and TB are complicated by a third epidemic of MDR-TB. This third epidemic requires urgent attention to achieve more rapid diagnosis, to develop new therapeutic regimens, and to address the social and hospital environment ot care for these individuals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8275781     DOI: 10.1378/chest.105.1.45

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

Review 1.  Tuberculosis in pregnancy and the puerperium.

Authors:  P Ormerod
Journal:  Thorax       Date:  2001-06       Impact factor: 9.139

Review 2.  The rising incidence of tuberculosis.

Authors:  F J Millard
Journal:  J R Soc Med       Date:  1996-09       Impact factor: 5.344

3.  Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.

Authors:  B P Kelly; S K Furney; M T Jessen; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

4.  Ciprofloxacin once daily versus twice daily for the treatment of pulmonary tuberculosis.

Authors:  H Bergstermann; A Rüchardt
Journal:  Infection       Date:  1997 Jul-Aug       Impact factor: 3.553

5.  Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

6.  Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis.

Authors:  D A Rouse; S L Morris
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

7.  Enhanced interleukin-8 release and gene expression in macrophages after exposure to Mycobacterium tuberculosis and its components.

Authors:  Y Zhang; M Broser; H Cohen; M Bodkin; K Law; J Reibman; W N Rom
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

8.  A meta-analysis of drug resistant tuberculosis in Sub-Saharan Africa: how strongly associated with previous treatment and HIV co-infection?

Authors:  Asres Berhan; Yifru Berhan; Desalegn Yizengaw
Journal:  Ethiop J Health Sci       Date:  2013-11

Review 9.  Setting the standard: multidisciplinary hallmarks for structural, equitable and tracked antibiotic policy.

Authors:  Claas Kirchhelle; Paul Atkinson; Alex Broom; Komatra Chuengsatiansup; Jorge Pinto Ferreira; Nicolas Fortané; Isabel Frost; Christoph Gradmann; Stephen Hinchliffe; Steven J Hoffman; Javier Lezaun; Susan Nayiga; Kevin Outterson; Scott H Podolsky; Stephanie Raymond; Adam P Roberts; Andrew C Singer; Anthony D So; Luechai Sringernyuang; Elizabeth Tayler; Susan Rogers Van Katwyk; Clare I R Chandler
Journal:  BMJ Glob Health       Date:  2020-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.